The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform for the treatment of patients with asymptomatic severe ...
Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve implants to patients before they begin to show cardiac symptoms. The company ...
Edwards Lifesciences has persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis. The move is causing CMS to reconsider its previous stance on covering transcatheter ...
Edwards Lifesciences Corp., of Irvine, Calif., petitioned the Centers for Medicare & Medicaid Services to revise the Medicare coverage policy for transcatheter aortic valve replacement (TAVR) devices ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback